| 6.81 -0.15 (-2.16%) | 09-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.28 |
1-year : | 16.11 |
| Resists | First : | 10.51 |
Second : | 13.8 |
| Pivot price | 6.38 |
|||
| Supports | First : | 5.19 |
Second : | 4.32 |
| MAs | MA(5) : | 7.38 |
MA(20) : | 6.24 |
| MA(100) : | 6.75 |
MA(250) : | 6.05 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38 |
D(3) : | 40.1 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 15.81 | Low : | 2.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRTG ] has closed above bottom band by 48.7%. Bollinger Bands are 110.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.78 - 8.82 | 8.82 - 8.86 |
| Low: | 7.59 - 7.65 | 7.65 - 7.69 |
| Close: | 8.27 - 8.36 | 8.36 - 8.43 |
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 60.5 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 51 (K) |
| EPS | -5.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -92.7 % |
| Return on Equity (ttm) | -541.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | -90.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|